Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 127

Sort by

Sort Order Select

Journal Articles

A Single Next Generation Sequencing Assay for Detection of Driver Mutations, Translocations and Copy Number Alterations in Patients with Multiple Myeloma

Cecilia Bonolo De Campos, James B Smadbeck, Mariano Arribas, Neeraj Sharma, Gregory J Ahmann, Shaji K Kumar, A. Keith Stewart, Rafael Fonseca, P. Leif Bergsagel, Yan Asmann, Linda B. Baughn, Esteban Braggio

Blood (2022) 140 (Supplement 1): 7180–7181.

https://doi.org/10.1182/blood-2022-170749

Published: 2022

Journal Articles

Chronic Lymphocytic Leukemia in African Ancestry Population Is Characterized By Increased Telomere Erosion

Cecilia Bonolo De Campos, Chantal McCabe, Laura Ann Bruins, Daniel R. O'Brien, Sochilt Brown, Cristine Allmer, Yuan Xiao Zhu, Kari G Rabe, Sameer A. Parikh, Neil E. Kay, James R. Cerhan, Laura Z Rassenti, Richard R. Furman, J. Brice Weinberg, Danielle Brander, Marta Chesi, Susan L. Slager, Esteban Braggio

Blood (2022) 140 (Supplement 1): 4135–4136.

https://doi.org/10.1182/blood-2022-170944

Published: 2022

Journal Articles

Vκ*MYC Mouse Model Recapitulates Key Genomic Defining Events in Multiple Myeloma

Francesco Maura, David Coffey, Esteban Braggio, Caleb K Stein, Meaghen E Sharik, Megan T Du, Bachisio Ziccheddu, Gareth J. Morgan, Ola Landgren, P. Leif Bergsagel, Marta Chesi

Blood (2022) 140 (Supplement 1): 1540–1541.

https://doi.org/10.1182/blood-2022-166614

Published: 2022

Journal Articles

LP-118, a Novel BCL2 Inhibitor, Shows Potent in Vitro Anti-Myeloma Activity

Rodrigo Fonseca, Yuan Xiao Zhu, P. Leif Bergsagel, Marta Chesi, Akhilesh Pandey, Kiran Mangalaparthi, Yi Chen, Felai Tan, Stephen P. Anthony, Yu Chen, Yue Shen, Bing Dai, Esteban Braggio, Rafael Fonseca

Blood (2022) 140 (Supplement 1): 7129–7130.

https://doi.org/10.1182/blood-2022-167372

Published: 2022

Journal Articles

Treatment Patterns and Outcomes of Patients with Chronic Lymphocytic Leukemia with TP53 Mutations

Steven R Hwang, Yucai Wang, Kari G Rabe, Rong He, Saad S. Kenderian, Eli Muchtar, Paul J. Hampel, Neil E. Kay, Timothy G. Call, Amber Koehler, Amy L Behnken, Jose F. Leis, Esteban Braggio, Min Shi, David S. Viswanatha, Daniel L. Van Dyke, Susan L. Slager, Sameer A. Parikh, Wei Ding

Blood (2022) 140 (Supplement 1): 12390–12392.

https://doi.org/10.1182/blood-2022-165508

Published: 2022

Journal Articles

Genomic Pathways Differentiating IgM-MGUS from Waldenstrom Macroglobulinemia: The Integrated microRNA and Gene Expression Landscape

Karan Chohan, Jonas Paludo, Surendra Dasari, Jithma P. Abeykoon, Prashant Kapoor, Esteban Braggio, Michelle K. Manske, Aneel Paulus, Craig B. Reeder, Sikander Ailawadhi, Asher Chanan-Khan, Robert A. Kyle, Morie A Gertz, Anne J. Novak, Stephen M. Ansell

Blood (2022) 140 (Supplement 1): 9242–9243.

https://doi.org/10.1182/blood-2022-167543

Published: 2022

Journal Articles

Potential Drivers of Acquired Resistance to Idelalisib in CLL Patients

Saurabh Yadav, Jasneet Khalsa, Ishwarya Murali, Richard R. Furman, Neil E. Kay, Esteban Braggio, Jennifer R. Brown

Blood (2022) 140 (Supplement 1): 12373–12374.

https://doi.org/10.1182/blood-2022-166648

Published: 2022

Journal Articles

Progression and survival of MBL: a screening study of 10 139 individuals

Susan L. Slager, Sameer A. Parikh, Sara J. Achenbach, Aaron D. Norman, Kari G. Rabe, Nicholas J. Boddicker, Janet E. Olson, Geffen Kleinstern, Connie E. Lesnick, Timothy G. Call, James R. Cerhan, Celine M. Vachon, Neil E. Kay, Esteban Braggio, Curtis A. Hanson, Tait D. Shanafelt

Blood (2022) 140 (15): 1702–1709.

https://doi.org/10.1182/blood.2022016279

Published: 2022

Includes: Supplemental data

Journal Articles

Long-term outcomes for ibrutinib–rituximab and chemoimmunotherapy in CLL: updated results of the E1912 trial

Blood (2022) 140 (2): 112–120.

https://doi.org/10.1182/blood.2021014960

Published: 2022

Includes: Supplemental data

Journal Articles

Measurable residual disease does not preclude prolonged progression-free survival in CLL treated with ibrutinib

Blood (2021) 138 (26): 2810–2827.

https://doi.org/10.1182/blood.2020010146

Published: 2021

Includes: Supplemental data

Journal Articles

B Cell Receptor Signaling Drives APOBEC3 Expression Via Direct Enhancer Regulation in Chronic Lymphocytic Leukemia B Cells

Zhiquan Wang, Huihuang Yan, Justin C. Boysen, Charla R. Secreto, Esteban Braggio, Susan L. Slager, Sameer A. Parikh, Neil E. Kay

Blood (2021) 138 (Supplement 1): 3313.

https://doi.org/10.1182/blood-2021-153214

Published: 2021

Journal Articles

Relationship and Susceptibility to Serious Infections Among Monoclonal B-Cell Lymphocytosis (MBL), Monoclonal Gammopathy of Undetermined Significance (MGUS), and Clonal Hematopoiesis (CH) Premalignant Conditions

Nicholas J. Boddicker, Sameer A. Parikh, Geffen Kleinstern, Aaron D. Norman, Kari G. Rabe, Timothy G. Call, Janet E. Olson, Angela Dispenzieri, David L Murray, S. Vincent Rajkumar, Shaji Kumar, James R. Cerhan, Neil E. Kay, Esteban Braggio, Curtis A. Hanson, Tait Shanafelt, Celine M. Vachon, Susan L. Slager

Blood (2021) 138 (Supplement 1): 3739.

https://doi.org/10.1182/blood-2021-151929

Published: 2021

Journal Articles

Prevalence and Overall Survival of Low Count Monoclonal B-Cell Lymphocytosis (LC-MBL): A Screening Study of 8,297 Individuals from the Mayo Clinic Biobank

Susan L. Slager, Sameer A. Parikh, Sara J. Achenbach, Geffen Kleinstern, Nicholas J. Boddicker, Aaron D. Norman, Kari G. Rabe, Connie E. Lesnick, Timothy G. Call, Janet E. Olson, James R. Cerhan, Neil E. Kay, Celine M. Vachon, Esteban Braggio, Curtis A. Hanson, Tait Shanafelt

Blood (2021) 138 (Supplement 1): 2632.

https://doi.org/10.1182/blood-2021-153320

Published: 2021

Journal Articles

TP53 Aberrations and Outcomes in MBL and Untreated CLL

Rosalie Griffin Waller, Julia E. Wiedmeier, Nicholas J. Boddicker, Geffen Kleinstern, Cecilia Bonolo De Campos, Daniel L. Van Dyke, Huihuang Yan, Celine M. Vachon, Daniel R. O'Brien, Cristine Allmer, Kari G. Rabe, James R. Cerhan, Timothy G. Call, Sameer A. Parikh, Neil E. Kay, Esteban Braggio, Susan L. Slager

Blood (2021) 138 (Supplement 1): 2618.

https://doi.org/10.1182/blood-2021-153602

Published: 2021

Journal Articles

Identifying Mechanisms Associated with Venetoclax Resistance in Multiple Myeloma (MM)

Yuan Xiao Zhu, Laura Ann Bruins, Joseph Ahmann, Cecilia Bonolo De Campos, Esteban Braggio, Xianfeng Chen, Mariano Arribas, Susie Darvish, Gregory J Ahmann, Rafael Fonseca

Blood (2021) 138 (Supplement 1): 2668.

https://doi.org/10.1182/blood-2021-153747

Published: 2021

Journal Articles

Utilization of a Targeted Next Generation Sequencing Assay to Identify Copy Number Alterations in Chronic Lymphocytic Leukemia and Monoclonal B-Cell Lymphocytosis

Julia E. Wiedmeier, Chantal McCabe, Daniel R. O'Brien, Nicholas J. Boddicker, Rosalie Griffin Waller, Cecilia Bonolo De Campos, James R. Cerhan, Sameer A. Parikh, Neil E. Kay, Huihuang Yan, Daniel L. Van Dyke, Susan L. Slager, Esteban Braggio

Blood (2021) 138 (Supplement 1): 4677.

https://doi.org/10.1182/blood-2021-153001

Published: 2021

Journal Articles

Outcomes of Patients with Chronic Lymphocytic Leukemia (CLL) Treated with the Combination of Ibrutinib (I) and Venetoclax (V; I+V) after Progression on I Alone (V-naïve) or after Progression on Sequential I and V (Double-Refractory)

Blood (2021) 138 (Supplement 1): 1560.

https://doi.org/10.1182/blood-2021-151668

Published: 2021

Journal Articles

The CLL International Prognostic Index predicts outcomes in monoclonal B-cell lymphocytosis and Rai 0 CLL

Sameer A. Parikh, Kari G. Rabe, Neil E. Kay, Timothy G. Call, Wei Ding, Jose F. Leis, Saad S. Kenderian, Eli Muchtar, Yucai Wang, Amber B. Koehler, Susan M. Schwager, Connie E. Lesnick, Geffen Kleinstern, Daniel Van Dyke, Curtis A. Hanson, Esteban Braggio, Susan L. Slager, Tait D. Shanafelt

Blood (2021) 138 (2): 149–159.

https://doi.org/10.1182/blood.2020009813

Published: 2021

Includes: Supplemental data

Journal Articles

ROR1 targeting with the antibody-drug conjugate VLS-101 is effective in Richter syndrome patient–derived xenograft mouse models

Tiziana Vaisitti, Francesca Arruga, Nicoletta Vitale, Thanh-Trang Lee, Mira Ko, Amy Chadburn, Esteban Braggio, Arianna Di Napoli, Andrea Iannello, John N. Allan, Langdon L. Miller, Brian J. Lannutti, Richard R. Furman, Katti A. Jessen, Silvia Deaglio

Blood (2021) 137 (24): 3365–3377.

https://doi.org/10.1182/blood.2020008404

Published: 2021

Includes: Supplemental data

Journal Articles

Natural history of monoclonal B-cell lymphocytosis among relatives in CLL families

Blood (2021) 137 (15): 2046–2056.

https://doi.org/10.1182/blood.2020006322

Published: 2021

Includes: Supplemental data

NARROW

A Single Next Generation Sequencing Assay for Detection of Driver Mutations, Translocations and Copy Number Alterations in Patients with Multiple Myeloma

Chronic Lymphocytic Leukemia in African Ancestry Population Is Characterized By Increased Telomere Erosion

Vκ*MYC Mouse Model Recapitulates Key Genomic Defining Events in Multiple Myeloma

LP-118, a Novel BCL2 Inhibitor, Shows Potent in Vitro Anti-Myeloma Activity

Treatment Patterns and Outcomes of Patients with Chronic Lymphocytic Leukemia with TP53 Mutations

Genomic Pathways Differentiating IgM-MGUS from Waldenstrom Macroglobulinemia: The Integrated microRNA and Gene Expression Landscape

Potential Drivers of Acquired Resistance to Idelalisib in CLL Patients

Progression and survival of MBL: a screening study of 10 139 individuals

Long-term outcomes for ibrutinib–rituximab and chemoimmunotherapy in CLL: updated results of the E1912 trial

Measurable residual disease does not preclude prolonged progression-free survival in CLL treated with ibrutinib

B Cell Receptor Signaling Drives APOBEC3 Expression Via Direct Enhancer Regulation in Chronic Lymphocytic Leukemia B Cells

Relationship and Susceptibility to Serious Infections Among Monoclonal B-Cell Lymphocytosis (MBL), Monoclonal Gammopathy of Undetermined Significance (MGUS), and Clonal Hematopoiesis (CH) Premalignant Conditions

Prevalence and Overall Survival of Low Count Monoclonal B-Cell Lymphocytosis (LC-MBL): A Screening Study of 8,297 Individuals from the Mayo Clinic Biobank

TP53 Aberrations and Outcomes in MBL and Untreated CLL

Identifying Mechanisms Associated with Venetoclax Resistance in Multiple Myeloma (MM)

Utilization of a Targeted Next Generation Sequencing Assay to Identify Copy Number Alterations in Chronic Lymphocytic Leukemia and Monoclonal B-Cell Lymphocytosis

Outcomes of Patients with Chronic Lymphocytic Leukemia (CLL) Treated with the Combination of Ibrutinib (I) and Venetoclax (V; I+V) after Progression on I Alone (V-naïve) or after Progression on Sequential I and V (Double-Refractory)

The CLL International Prognostic Index predicts outcomes in monoclonal B-cell lymphocytosis and Rai 0 CLL

ROR1 targeting with the antibody-drug conjugate VLS-101 is effective in Richter syndrome patient–derived xenograft mouse models

Natural history of monoclonal B-cell lymphocytosis among relatives in CLL families

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only